アブストラクト(24巻2号:神奈川歯学)

神奈川歯学

Japanese

Title : B型肝炎ウイルスと感染事故におけるHBIGおよびVaccine投与の疫学的感染予防効果 (2)
Subtitle : 原著
Authors : 木村友七*,**, 岩宮万里子*,**, 吉田直美*,**, 岩本朗子*,**, 笹田睦美*,**, 伊東利*,**, 菊池信弥*,**, 八木伸*,**, 檜垣旺夫***
Authors(kana) :
Organization : *神奈川歯科大学臨床病理学教室, **神奈川歯科大学臨床検査科, ***神奈川歯科大学小児歯科学教室
Journal : 神奈川歯学
Volume : 24
Number : 2
Page : 393-398
Year/Month : 1989 / 9
Article : 原著
Publisher : 神奈川歯科大学学会
Abstract : 「はじめに」 B型肝炎ウイルス(HBV)は, BlumbergのAu抗原の発見から, 免疫・疫学・基礎学ならびに臨床医学的研究と観察を基盤とした検索から, 病因と疾患との相互的因果関係の段階と病因制御が積極的に進められている. HBV腫瘍関連マーカーも重要視されてきている. HBV感染は, 輸血・血液製剤の輸入, 医療過誤, 母児間における垂直や水平感染, 接触による家族間の感染, 配偶者間感染などと, さらには施設間感染, 同性愛者間・薬物注入依存者間らと感染頻度が高率である. 医療法が複雑化や発展するにつれて, HBVをはじめとする医療上の感染対策が必要とされる. HBV感染の重要性や緊急性の度合に応じて, HBIG・HB Vaccineの投与が積極的にされている. 予防効果は, 非投与群とでは明らかにHBVの感染が阻止されている. 母児間感染, 配偶者間感染, 家族内感染, 医療事故による感染防止に投与されてB型肝炎の予防に効果的である. 本学におけるHBIG投与とVaccine接種効果について, 簡単に述べる.
Practice : 歯科学
Keywords : HBV感染の予防, HBIGとVaccine投与, HBs抗体推移

English

Title : Hepatitis B Virus and Epidemiological Study on Efficacy of HBIG and Vaccine for the Prevention of Type B Hepatitis After Accidental Exposures Among Medical Staffs (2)
Subtitle : Original article
Authors : Tomoshichi KIMURA*,**, Mariko IWAMIYA*,**, Naomi YOSHIDA*,**, Akiko IWAMOTO*,**, Mutsumi SASADA*,**, Satoshi ITO*,**, Nobuya KIKUCHI*,**, Shin YAGI*,**, Morio HIGAKI***
Authors(kana) :
Organization : *Department of Clinical Pathology, Kanagawa Dental College, **Department of Clinical Laboratries, Kanagawa Dental College, ***Department of Pedodontics, Kanagawa Dental College
Journal : Kanagawa Shigaku
Volume : 24
Number : 2
Page : 393-398
Year/Month : 1989 / 9
Article : Original article
Publisher : Kanagawa Odontological Society
Abstract : Abstract : The best method of preventing HBV is accurate perception on the part of the patient. There is a need for sufficient care regarding patient blood with HBsAg (+), HBeAg (+) and HBc high-antibody titer. The following is a report on a follow-up survey regarding antibody titer following dosages of HBIG 2V and 1V and administration of a vaccine along with dosage of HBIG 1V. 1. Dosage of HBIG 2V : (Female) Antibody titer was recognized two days following dosage. It continued for two weeks and disappeared after four weeks. (2) (Male) Antibody titer was recognized one day following dosage but disappeared after two weeks. 2. Dosage of HBIG 1V : (Female) Antibody titer (-) was recognized two days after dosage and nine days after dosage. It continued for about one month and disappeared after five months. 3. Administration of three vaccines and dosage of HBIG 1V : (Female) Antibody titer was recognized two days after HBIG 1V dosage and continued for 18 days but disappeared after three months. Antibody titer was recognized again after about eight months and showed signs of continuing for 13 months.
Practice : Dentistry
Keywords :